Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 438-445

  Igawa, Satoshi ^a   Watanabe, Reiko ^a   Ito, Ichiro ^a   Murakami, Haruyasu ^a   Takahashi, Toshiaki ^a   Nakamura, Yukiko ^a   Tsuya, Asuka ^a   Kaira, Kyoichi ^a   Naito, Tateaki ^a   Endo, Masahiro ^a   Yamamoto, Nobuyuki ^a   Kameya, Toru ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Chemotherapy; High grade non small cell neuroendocrine carcinoma; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; CAMPTOTHECIN; PLATINUM DERIVATIVE; TAXOID; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HIGH GRADE NON SMALL CELL NEUROENDOCRINE CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DISEASE COURSE; DRUG COMBINATION; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; NEUROENDOCRINE TUMORS; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TAXOIDS; VINBLASTINE;

EID: 77952546398     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.07.003     Document Type: Article

References (14)

1. Travis W.D., Linnoila R.I., Tsokos M.G., Hitchcock C.L., Nieman L., Chrousos G., et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991, 15:529-553.
2. Brambilla E., Travis W.D., Colby T.V., Corrin B., Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1068.
3. Jiang S.X., Kameya T., Shoji M., Dobashi Y., Shinada J., Yoshimura H. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998, 22:526-537.
4. Asamura H., Kameya T., Matsuno Y., Noguchi M., Tada H., Ishikawa Y., et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006, 24:70-76.
5. Doddoli C., Aragon A., Barlesi F., Chetaille B., Robitail S., Giudicelli R., et al. Large cell neuroendocrine carcinoma of the lung: an aggressive disease potentially treatable with surgery. Ann Thorac Surg 2004, 77:1168-1172.
6. Paci M., Cavazza A., Annessi V., Putrino I., Ferrari G., De Franco S., et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 2004, 77:1163-1167.
7. Mazières J., Daste G., Molinier L., Berjaud J., Dahan M., Delsol M., et al. Large cell neuroendocrine carcinoma of the lung: pathological study and clinical outcome of 18 resected cases. Lung Cancer 2002, 37:287-292.
8. Yamazaki S., Sekine I., Matsuno Y., Takei H., Yamamoto N., Kunitoh H., et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 2005, 49:217-223.
9. Giulio R., Alberto C., Alessandro M., et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRα, PDGFRβ, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005, 23:8774-8785.
10. Iyoda A., Hiroshima K., Moriya Y., Mizobuchi T., Otsuji M., Sekine Y., et al. Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg 2004, 77:1891-1895.
11. Pelosi G., Rodriguez J., Viale G., Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005, 29:179-187.
12. Gehan E.A., Tefft M.C. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?. J Natl Cancer Inst 2000, 92:205-216.
13. Iyoda A., Hiroshima K., Toyozaki T., Haga Y., Fujisawa T., Ohwada H., et al. Clinical characterization of pulmonary large cell neuroendocrine and large cell carcinoma with neuroendocrine morphology. Cancer 2001, 91:1992-2000.
14. Takei H., Asamura H., Maeshima A., Suzuki K., Kondo H., Niki T., et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002, 124:285-292.